Drug Profile
Alemtuzumab - Bayer/Sanofi/University of Cambridge
Alternative Names: Anti-CD52 monoclonal antibody; Campath; Campath-1H; LDP-03; Lemtrada; MabCampath; MabKampat; RemniqLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator University of Cambridge
- Developer Bayer HealthCare Pharmaceuticals Inc.; Dana-Farber Cancer Institute; German CLL Study Group; Ohio State University Comprehensive Cancer Center; Sanofi; Sanofi Oncology; University of California; University of Cologne
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic lymphocytic leukaemia; Multiple sclerosis
- Phase II T-cell prolymphocytic leukaemia
- Phase I/II Precursor cell lymphoblastic leukaemia-lymphoma
- No development reported Diffuse large B cell lymphoma; Graft-versus-host disease; Lymphoma; Sezary syndrome; T-cell lymphoma
- Discontinued Rheumatoid arthritis
Most Recent Events
- 29 Nov 2022 Phase-III development in Multiple sclerosis (In adolescents, In children) is ongoing in Belgium and Netherlands (IV) (NCT03368664)
- 13 Oct 2021 Updated efficacy and safety data from the phase III CARE-MS 1 follow-up TOPAZ trial in Multiple sclerosis presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2021)
- 13 Oct 2021 Updated safety and efficacy data from the phase III CARE-MS II trial in Multiple sclerosis presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2021)